Kohei Shitara, MD, discusses HERIZON-GEA-01 findings and how to individualize first-line treatment for HER2-positive advanced gastroesophageal adenocarcinoma.
Kohei Shitara, MD
Advertisement
Articles by Kohei Shitara, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutated HR+/HER2– Breast Cancer
2
Imneskibart Regimens Show Activity in ICI-Refractory Melanoma, NSCLC
3
Comparing Treatment Approaches in Second-Line Metastatic ccRCC
4
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
5